301 related articles for article (PubMed ID: 29268281)
1. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
2. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
5. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
Jubair L; Fallaha S; McMillan NAJ
Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
Jubair L; Lam AK; Fallaha S; McMillan NAJ
PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Zhen S; Hua L; Takahashi Y; Narita S; Liu YH; Li Y
Biochem Biophys Res Commun; 2014 Aug; 450(4):1422-6. PubMed ID: 25044113
[TBL] [Abstract][Full Text] [Related]
8. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
9. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy.
Aghamiri S; Talaei S; Roshanzamiri S; Zandsalimi F; Fazeli E; Aliyu M; Kheiry Avarvand O; Ebrahimi Z; Keshavarz-Fathi M; Ghanbarian H
Expert Opin Drug Deliv; 2020 Jun; 17(6):753-766. PubMed ID: 32281426
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer.
Jung HS; Rajasekaran N; Ju W; Shin YK
J Clin Med; 2015 May; 4(5):1126-55. PubMed ID: 26239469
[TBL] [Abstract][Full Text] [Related]
11. Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes.
Liu YC; Cai ZM; Zhang XJ
Asian J Androl; 2016; 18(3):475-9. PubMed ID: 26228041
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
13. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 therapies in experimental mouse models of cancer.
Estêvão D; Rios Costa N; da Costa RG; Medeiros R
Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
[TBL] [Abstract][Full Text] [Related]
15. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
16. Advances in the development of therapeutic nucleic acids against cervical cancer.
DiPaolo JA; Alvarez-Salas LM
Expert Opin Biol Ther; 2004 Aug; 4(8):1251-64. PubMed ID: 15268660
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.
Zhen S; Lu JJ; Wang LJ; Sun XM; Zhang JQ; Li X; Luo WJ; Zhao L
Transl Oncol; 2016 Dec; 9(6):498-504. PubMed ID: 27816686
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathways in HPV-associated cancers and therapeutic implications.
Chen J
Rev Med Virol; 2015 Mar; 25 Suppl 1():24-53. PubMed ID: 25752815
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6.
Yoshiba T; Saga Y; Urabe M; Uchibori R; Matsubara S; Fujiwara H; Mizukami H
Oncol Lett; 2019 Feb; 17(2):2197-2206. PubMed ID: 30675284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
